Meeting
2022 ASCO Genitourinary Cancers Symposium
Evaluation of compliance of next-generation sequencing (NGS) testing in stage IV genitourinary (GU) cancer patients (pts) and the effect of an EHR prompt (EP) on increasing frequency.
Authors
Sydney E. Cobrin
Astera Cancer Care, East Brunswick, NJ
Sydney E. Cobrin , Percy Yeung , Carina Cedeno , Stephanie Marks , Ellen A. Ronnen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 48)
DOI
10.1200/JCO.2022.40.6_suppl.048
Abstract #
48
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
RNAseq in addition to next generation sequencing in advanced genitourinary cancers reveals transcriptomic silencing of DNA mutations: Implications for resistance to targeted therapeutics.
First Author: Jacob J. Adashek
Poster
2019 Genitourinary Cancers Symposium
The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.
First Author: Alexandra Sokolova
Poster
2018 ASCO Annual Meeting
Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).
First Author: Joaquin Mateo
Poster
2024 ASCO Genitourinary Cancers Symposium
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
First Author: Sanjay Khanna